Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/5928Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Beasley, Richard | - |
| dc.contributor.author | Chang, Anne B. | - |
| dc.date.accessioned | 2024-06-20T00:28:49Z | - |
| dc.date.available | 2024-06-20T00:28:49Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.citation | The Lancet. Respiratory medicine, 2023 (11) 5 p.393-395 | en |
| dc.identifier.uri | https://dora.health.qld.gov.au/qldresearchjspui/handle/1/5928 | - |
| dc.description.abstract | Competing Interests: RB declares grant funding to the Medical Research Institute of New Zealand from AstraZeneca, Genentech, and the New Zealand Health Research Council and personal consulting fees from AstraZeneca, Cipla, Avillion, Health Research Council (New Zealand), CSL Seqirus, and Teva Pharmaceuticals. ABC declares no competing interests. | - |
| dc.title | Is tezepelumab the ubiquitous biologic for severe asthma? | - |
| dc.identifier.doi | 10.1016/S2213-2600(22)00530-6 | - |
| dc.relation.url | https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,athens&db=mdc&AN=36702145&site=ehost-live | - |
| dc.identifier.journaltitle | The Lancet. Respiratory medicine | - |
| dc.identifier.risid | 4333 | - |
| dc.description.pages | 393-395 | - |
| dc.description.volume | 11 | - |
| dc.description.issue | 5 | - |
| item.grantfulltext | none | - |
| item.fulltext | No Fulltext | - |
| Appears in Sites: | Children's Health Queensland Publications | |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.